Christopher Halliday Selected Research

Christopher Halliday Research Topics

9	Cardiovascular Diseases (Cardiovascular Disease) 01/2020 - 01/2016
5	Inflammation (Inflammations) 01/2020 - 08/2017
3	Atherosclerosis 12/2019 - 09/2016
3	Chronic Renal Insufficiency 11/2019 - 01/2018
3	Vascular Calcification 01/2019 - 01/2018
2	Myocardial Infarction 01/2021 - 11/2019
2	Acute Coronary Syndrome 01/2021 - 12/2019
2	Coronary Disease (Coronary Heart Disease) 01/2020 - 11/2019
2	Atherosclerotic Plaque (Atheroma) 12/2019 - 01/2016
1	Cytokine Release Syndrome 01/2021
1	Type 2 Diabetes Mellitus (MODY) 01/2021
1	Stroke (Strokes) 01/2021
1	COVID-19 01/2021
1	Acute-Phase Reaction 01/2020
1	Metabolic Syndrome (Dysmetabolic Syndrome X) 08/2017

11	apabetaloneIBA 01/2021 - 01/2016
4	omega-Chloroacetophenone (Mace)IBA 01/2021 - 01/2019
4	Proteins (Proteins, Gene)FDA Link 01/2020 - 01/2016
3	Apolipoprotein A-I (Apolipoprotein A1)IBA 10/2016 - 01/2016
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 12/2019 - 11/2019
2	HDL LipoproteinsIBA 12/2019 - 01/2016
2	Alkaline PhosphataseIBA 11/2019 - 01/2018
2	CholesterolIBA 08/2017 - 01/2016
1	Insulin (Novolin)FDA Link 01/2021
1	Interferon-gamma (Interferon, gamma)IBA 01/2021
1	InterleukinsIBA 01/2021
1	Poly I-CIBA 01/2021
1	Fibrinogen (Factor I)FDA Link 01/2020
1	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 01/2020
1	CytokinesIBA 01/2020
1	C-Reactive ProteinIBA 11/2019
1	ProteomeIBA 05/2018
1	Complement System Proteins (Complement)IBA 08/2017

1	Therapeutics 01/2021
1	Secondary Prevention 11/2019